Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,385
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
AUTO CAR T cell therapy
Autolus GmbH
Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy
1 trial -
AUTO1
Autolus GmbH
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
2 trials -
AUTO1, Cyclophosphamide 500 mg Powder for Solution for Injection or Infusion, Fludara 50 mg powder for solution for injection or infusion
Autolus GmbH
Systemic Lupus Erythematosus with Active Lupus Nephritis
1 trial -
AUTO1, MabThera 500 mg concentrate for solution for infusion, AUTO4, MabThera 100 mg concentrate for solution for infusion
Autolus GmbH
Potential malignancy in patients who received treatment with Autolus CAR T cell therapy.
1 trial -
AUTO2
Autolus GmbH
Multiple Myeloma
1 trial -
AUTO3
Autolus GmbH
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
1 trial -
AUTO3 (CD19/22 CAR T cells
Autolus GmbH
B Acute Lymphoblastic Leukemia
1 trial -
AUTO4
Autolus GmbH
T Cell Non-Hodgkin Lymphoma
1 trial -
Genoxal 200 mg polvo para solución inyectable y para perfusión, Fludarabina Teva 25 mg/ml concentrado para solución para perfusión o inyección EFG, AUTO1, Paracetamol MABO 500 mg comprimidos
Autolus GmbH
Relapsed or refractory B cell acute lymphoblastic leukaemia
1 trial -
Obecabtagene Autoleucel
Autolus GmbH
Acute Lymphoblastic Leukemia
1 trial -
Obecabtagene autoleucel
Autolus GmbH
Acute Lymphocytic Leukemia (ALL)
1 trial -
Obecabtagene autoleucel
Autolus GmbH
Lupus Nephritis
1 trial -
A SINGLE-ARM, OPEN-LABEL, PHASE I STUDY TO DETERMINE THE SAFETY, TOLERABILITY, AND PRELIMINARY EFFICACY OF OBE-CEL IN PARTICIPANTS WITH REFRACTORY PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS
Autolus GmbH
Refractory Progressive Multiple Sclerosis
1 trial -
A Single-Arm, Open-Label, Phase 1 Study to Determine the Safety, Tolerability and Preliminary Efficacy of Obecabtagene Autoleucel in Patients with Severe, Refractory Systemic Lupus Erythematosus
Autolus GmbH
Severe, Refractory Systemic Lupus Erythematosus
1 trial -
Obecabtagene autoleucel (obe-cel)
Autolus GmbH
Progressive Multiple Sclerosis
1 trial -
Obecabtagene autoleucel (obe-cel)
Autolus GmbH
Systemic Lupus Erythematosus
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources